The Wolverine stack: BPC-157 and TB-500 doses that circulate, and the one study that tested them
What each compound's own studies show, the single rat study that tested the pair, and where the 250 to 500 microgram and 2.5 milligram figures actually come from.
At a glance
What the Wolverine stack is
The Wolverine stack is the community name for BPC-157 combined with TB-500, two peptides discussed for soft-tissue healing. BPC-157's evidence is animal work plus three uncontrolled human pilots; TB-500 is a fragment of thymosin beta-4, whose parent molecule has been in human trials. A stack cannot carry a stronger evidence tier than its weakest component, which here is observational human.
Three indexed publications mention both compounds, and one of them, a 2026 rat study of Achilles tendon healing, actually tested the pair; that is the entire combination evidence. The doses that circulate, 250 to 500 micrograms of BPC-157 once or twice daily with 2 to 2.5 milligrams of TB-500 twice weekly, have not been tested for any outcome and are reported here so a reader knows their origin.
The Wolverine stack in two minutes
What it is. BPC-157, a fragment of a gastric-juice protein, combined with TB-500, a fragment of thymosin beta-4. Named in fitness communities after the comic-book character who heals instantly. It is a community construct; no clinic, trial or regulator defined it.
What has been tested. One study, in rats, in 2026: BPC-157 and TB-500 alone and together on Achilles tendon healing, with higher load-to-failure in treated groups than controls. That is the whole of the combination evidence. Nothing in people.
What circulates. 250 to 500 micrograms of BPC-157 once or twice daily near the injury, plus 2 to 2.5 milligrams of TB-500 twice weekly, for four to six weeks. These figures come from forums and clinic pages, not studies.
Status. Neither compound is approved anywhere. BPC-157 is prohibited in sport under WADA S0 and TB-500 under S2, both at all times.
Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.
Each component on its own evidence
Each component carries its own tier. Adding compounds together does not add their evidence together.
Papers that name every component
Indexed papers that mention every component, quoted. A count of zero is the finding, not a gap in this page.
-
This study aims to evaluate the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in a rat model.
Sourcepmid-42542926· quoted verbatim from the abstract -
To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide]) for musculoskeletal recovery and enhancement in animal and human models.
Sourcepmid-42578445· quoted verbatim from the abstract -
A retrospective study was done at the Institute for Hormonal Balance in Orlando, Florida, USA to see whether intra-articular injection of the peptide BPC 157, alone or combined with TB4, helped relieve knee pain.
Sourcepmid-34324435· quoted verbatim from the abstract
Wolverine stack dosage: what circulates versus what any study used
Kept in separate rows so a reader can see that the community figures and the study figures never meet.
| Figure | Dose | Schedule | Basis |
|---|---|---|---|
| BPC-157, commonly reported | 250 to 500 µg subcutaneous, near the injury | Once or twice daily, 4 to 6 weeks | Untested for these uses |
| TB-500, commonly reported | 2 to 2.5 mg subcutaneous | Twice weekly for 4 to 6 weeks, then weekly | Untested for these uses |
| The pair, in the one study | Rat Achilles tendon model; doses per kilogram of rat | Post-injury course | Higher load to failure than controls; not a human dose |
| BPC-157, human data | 10 and 20 mg intravenous, single infusion | Once, 24 h observation | Two healthy adults; safety only |
| Thymosin β4, human data | Eye drops and topical gels in trials of the parent molecule | Weeks | Different formulation and route from injected TB-500 |
The community schedule pairs a daily compound with a twice-weekly one on the reasoning that BPC-157 acts locally and briefly while TB-500 acts systemically and longer. That reasoning is plausible and has never been measured in a person.
Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.
Why people combine them, and what the mechanisms actually are
BPC-157 is proposed to act on nitric-oxide signalling and growth-factor receptors and to promote new blood vessels; TB-500 is a fragment of thymosin beta-4, an actin-binding protein involved in cell migration, and is proposed to help cells move into a wound. Two different mechanisms with one shared outcome, tissue repair, is the whole argument for stacking them. It is a hypothesis about additive effect, and the single rat study is the only test of it. Notably, that study reported effects for each compound alone as well, so it does not show that the pair beats either one.
Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.
Who discusses using it, and the cautions that recur
- Athletes. The largest audience and the group for whom both compounds are prohibited at all times; both are detectable.
- Cancer, active or recent. Both compounds promote blood-vessel growth or cell migration in animals; both appear on every review's caution list for the same theoretical reason.
- Blood-pressure medication. BPC-157 shifts blood pressure in rats through nitric oxide; interactions are unstudied.
- Anyone relying on product labels. Two unregulated injectables double the exposure to identity, purity and impurity problems; a certificate of analysis matched to each batch is the only check.
Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.
Common mistakes in how the Wolverine stack is discussed
- Treating the name as evidence. A memorable name is not a studied regimen.
- Adding the animal literatures together. Hundreds of rat papers on BPC-157 and a trial record for thymosin β4 in eyes and skin do not sum to evidence for injected TB-500 plus BPC-157 in a tendon.
- Quoting the 2026 rat study as proof of synergy. It found effects in the treated groups; it did not establish that the combination outperformed either compound.
- Calling TB-500 "thymosin beta-4". Marketed TB-500 is usually a short fragment; the human trials used the full protein in eye drops and gels.
Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.
Open questions
- Whether the combination outperforms either compound alone, in any species, has not been tested.
- No human study of the combination exists, and none is registered.
- Whether injected TB-500 fragments behave like the thymosin β4 used in human eye and wound trials is unknown.
Questions people ask
What is the Wolverine stack?
BPC-157 combined with TB-500, named in fitness communities for the comic-book character's healing. It is a community construct, not a studied regimen.
Has the BPC-157 and TB-500 combination been studied?
Once, in rats: a 2026 study of Achilles tendon healing tested each compound and the pair. No human study has tested the combination.
What Wolverine stack doses circulate?
Commonly 250 to 500 micrograms of BPC-157 subcutaneously once or twice daily near the injury, with 2 to 2.5 milligrams of TB-500 twice weekly, for four to six weeks. None of these figures has been tested for any outcome.
Is the Wolverine stack legal or allowed in sport?
BPC-157 is prohibited under WADA category S0 and TB-500 under S2, both at all times. Neither is an approved medicine.
Why combine a gastric peptide fragment with a thymosin fragment?
The reasoning is that they act through different proposed mechanisms, nitric-oxide and growth-factor signalling for BPC-157 and actin-binding cell migration for TB-500, so their effects might add. That is a hypothesis; the one rat study is the only test of it.
Sources
Full citations. Every quoted claim above links to one of these.
- 1Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
pmid-42542926· · peer-reviewed - 2Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
pmid-42578445· · peer-reviewed - 3Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
pmid-34324435· · peer-reviewed
Reference card
- Stack
- BPC-157 + TB-500
- Strongest possible tier
- Observational, human
- Studies of the combination
- 3 indexed
- Component evidence
- BPC-157: 228 publications, 0 RCTs · TB-500: 1,257 publications, 7 RCTs
- Sources in ledger
- 3
Figures are as published in each source and are not recommendations. Print or save this card with its date.
Last reviewed and what changed
- · Reviewed by Adam Mirando, PharmD, on 2026-09-29.
- · Written guide added (quick answer, dosage chart, rationale, cautions, common mistakes); page moved to the v2 stack layout with an intent-driven H1.
- · Named as the Wolverine stack (the query people use: 7,428 clickstream, 27,100 Ads searches a month); summary rewritten; five FAQs added; title and description within budget.
- · Stack record generated from research/registry.json plan; 3 combination claims drafted extractively by scripts/draft_claims.py.